8. Gatheral T, Kumar N, Sansom B, et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. COPD, 2014, 11(6): 605-614.
[2]
13. Stannard WA, Chilvers MA, Rutman AR, et al. Diagnostic testing of patients suspected of primary ciliary dyskinesia. Am J Respir Crit Care Med, 2010, 181(4): 307-314.
[3]
14. Valdés L, Huggins JT, Gude F, et al. Characteristics of patients with yellow nail syndrome and pleural effusion. Respirology, 2014, 19(7): 985-992.
[4]
15. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med, 2014, 189(5): 576-585.
18. Cantón R, Cobos N, de Gracia J, et al. Antimicrobial therapy for pulmonarpathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect, 2005, 11(9): 690-703.
[7]
19. Angrill J, Agustí C, de Celis R, et al. Bacterial colonization in patients with bronchiectasis: microbiological pattern and risk factors. Thorax, 2002, 57(1): 15-19.
[8]
27. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med, 2014, 189(8): 975-982.
[9]
28. Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J, 2007, 37(7): 495-498.
[10]
29. Dhar R, Anwar GA, Bourke SC, et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax, 2010, 65(6): 553.
[11]
30. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax, 2013, 68(9): 812-817.
[12]
31. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomized study. Eur Respir J, 2013, 41(5): 1107-1115.
[13]
32. Gao YH, Guan WJ, Xu G, et al. Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. PLoS One, 2014, 9: e90047.
[14]
34. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cysticfibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet, 2012, 380(9842): 660-667.
[15]
36. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust, 2010, 193(6): 356-365.
[16]
41. Chan SC, Shum DK, Ip MS. Sputum sol neutrophil elastase activity in bronchiectasis: differential modulation by syndecan-1. Am J Respir Crit Care Med, 2003, 168(2): 192-198.
[17]
42. Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med, 2013, 107(4): 524-533.
[18]
43. De Soyza A, Pavord I, Elborn JS, et al. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J, 2015, 46(4): 1021-1032.
[19]
44. Konstan MW, Doring G, Heltsche SL, et al. A randomized double blind, placebo controlled phase 2 trial of BIIL284BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros, 2014, 13(2): 148-155.
[20]
47. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J, 2009, 34(5): 1086-1092.
[21]
48. Lee AL, Burge A, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev, 2013, (5): CD008351.
[22]
49. Ong HK, Lee AL, Hill CJ, et al. Effects of pulmonary rehabilitation in bronchiectasis: a retrospective study. Chron Respir Dis, 2011, 8(1): 21-30.
[23]
50. Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med, 2012, 106(5): 661-667.
[24]
51. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J, 2011, 38(5): 1071-1080.
[25]
53. Wilkinson M, Sugumar K, Milan SJ, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev, 2014, (5): CD001289.
2. Munro NC, Han LY, Currie DC, et al. Radiological evidence of progression of bronchiectasis. Respir Med, 1992, 86(5): 397-401.
[28]
3. Suarez-Cuartin G, Chalmers JD, Sibila O. Diagnostic challenges of bronchiectasis. Respir Med, 2016, 116: 70-77.
[29]
4. Guan WJ, Gao YH, Xu G, et al. Aetiology of bronchiectasis in Guangzhou, southern China. Respirology, 2015, 20(5): 739-748.
[30]
5. Anwar GA, McDonnell MJ, Worthy SA, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med, 2013, 107(7): 1001-1007.
[31]
6. Lonni S, Chalmers JD, Goeminne PC, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc, 2015, 12(12): 1764-1770.
[32]
7. Ni Y, Shi G, Yu Y, et al. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1465-1475.
[33]
9. Agarwal R1, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy, 2013, 43(8): 850-873.
[34]
10. Puéchal X, Génin E, Bienvenu T, et al. Poor survival in rheumatoid arthritis associated with bronchiectasis: a family-based cohort study. PLoS One, 2014, 9(10): e110066.
[35]
11. Swinson DR, Symmons D, Suresh U, et al. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol, 1997, 36(6): 689-691.
[36]
12. Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med, 2013, 188(8): 913-922.
[37]
16. Pasteur MC, Bilton D, Hill AT. British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax, 2010, 65(suppl 1): i1-i58.
[38]
20. Roberts ME, Lowndes L, Milne DG, et al. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Intern Med J, 2012, 42(6): e129-e136.
[39]
21. Ten Hacken NH, Kerstjens HA. Bronchiectasis. BMJ Clin Evid, 2011, 2011. pii: 1507.
[40]
22. Lobue PA. Inhaled tobramycin: not just for cystic fibrosis anymore? Chest, 2005, 127(4): 1098-1101.
[41]
23. Rubin BK, Williams RW. Aerosolized antibiotics for noncystic fibrosis bronchiectasis. Respiration, 2014, 88(3): 177-184.
[42]
24. Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin fo acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest, 2006, 130(5): 1503-1510.
[43]
25. Drobnic ME, Su？é P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother, 2005, 39(1): 39-44.
[44]
26. Serisier DJ. The evidence base for non-CF bronchiectasis is finally evolving. Respirology, 2014, 19(3): 295-297.
35. Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics--Part2: Advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration, 2011, 81(1): 75-87.
[47]
37. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax, 2005, 60(3): 239-243.
[48]
38. Martínez-García Má, Soler-Catalu？a JJ, Catalán-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest, 2012, 141(2): 461-468.
[49]
39. Holme J, Tomlinson JW, Stockley RA, et al. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J, 2008, 32(4): 1047-1052.
[50]
40. Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med, 2014, 2(6): 455-463.
46. Tambascio J, de Souza HC, Martinez JA, et al. The influence of purulence on ciliary and cough transport in bronchiectasis. Respir Care, 2013, 58(12): 2101-2106.
[53]
52. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax, 2014, 69(12): 1073-1079.
